Three-dimensional structure of Fab R19.9, a monoclonal murine antibody specific for the p-azobenzenearsonate group. 1989

M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
Département d'Immunologie, Institut Pasteur, Paris, France.

The crystal structure of Fab R19.9, derived from an anti-p-azobenzenearsonate monoclonal antibody, has been determined and refined to 2.8-A resolution by x-ray crystallographic techniques. Monoclonal antibody R19.9 (IgG2b kappa) shares some idiotopes with a major idiotype (CRIA) associated with A/J anti-p-azobenzenearsonate antibodies. The amino acid sequences of the variable (V) parts of the heavy (VH) and light (VL) polypeptide chains of monoclonal antibody R19.9 were determined through nucleotide sequencing of their mRNAs. The VL region is very similar to that of CRIA-positive anti-p-azobenzenearsonate antibodies as is VH, except for its third complementarity-determining region, which is three amino acids longer; it makes a loop, unique to R19.9, that protrudes into the solvent. A large number of tyrosine residues in the complementarity-determining region of VH and VL, with their side chains pointing towards the solvent, may have an important function in antigen binding.

UI MeSH Term Description Entries
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D007140 Immunoglobulin Fab Fragments Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fab Fragment,Fab Fragments,Ig Fab Fragments,Immunoglobulins, Fab Fragment,Fab Immunoglobulin Fragments,Immunoglobulin Fab Fragment,Immunoglobulins, Fab,Fab Fragment Immunoglobulins,Fab Fragment, Immunoglobulin,Fab Fragments, Immunoglobulin,Fragment Immunoglobulins, Fab,Fragment, Fab,Immunoglobulin Fragments, Fab
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010132 p-Azobenzenearsonate A hapten capable of eliciting both antibody formation and delayed hypersensitivity when bound to aromatic amino acids, polypeptides or proteins. It is used as an immunologic research tool. Azophenylarsonate,para-Azobenzenearsonate,p Azobenzenearsonate,para Azobenzenearsonate
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D003460 Crystallization The formation of crystalline substances from solutions or melts. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Crystalline Polymorphs,Polymorphism, Crystallization,Crystal Growth,Polymorphic Crystals,Crystal, Polymorphic,Crystalline Polymorph,Crystallization Polymorphism,Crystallization Polymorphisms,Crystals, Polymorphic,Growth, Crystal,Polymorph, Crystalline,Polymorphic Crystal,Polymorphisms, Crystallization,Polymorphs, Crystalline
D003461 Crystallography The branch of science that deals with the geometric description of crystals and their internal arrangement. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Crystallographies
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
May 1986, British journal of haematology,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
September 1994, Acta crystallographica. Section D, Biological crystallography,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
November 1996, Acta crystallographica. Section D, Biological crystallography,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
January 1977, Methods in enzymology,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
April 1997, Journal of molecular biology,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
August 2000, Acta crystallographica. Section D, Biological crystallography,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
February 1987, Molecular immunology,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
November 1992, Nature,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
September 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
M B Lascombe, and P M Alzari, and G Boulot, and P Saludjian, and P Tougard, and C Berek, and S Haba, and E M Rosen, and A Nisonoff, and R J Poljak
April 1991, Biochemistry,
Copied contents to your clipboard!